ABOUT US

Transforming Precision Medicine with Multimodal AI

BioAI is an AI-powered biomarker and digital pathology company supporting pharma, research and laboratory partners through biomarker-focused services, AI model development, external validation and Research Use Only product development.

Our Mission

At BioAI, our mission is to develop AI-powered precision biomarkers and discover novel drug targets to accelerate clinical R&D and advance precision oncology.

Our Purpose

Our purpose is to develop AI solutions for precision oncology research that can help advance patient care in the future.

Our Values

Innovation

We are dedicated to innovation, continuously advancing AI methods for biomarker research and precision oncology.

Patient Impact

Our work aims to contribute to more personalized cancer care in the future, starting with better biomarker research today.

Integrity

Upholding the highest ethical standards is essential in our field where research and development directly impact patient care and also often involve sensitive information. From partner and patient confidentiality to ethical AI, we maintain integrity in all aspects of operations.

Collaboration

BioAI believes in the power of interdisciplinary collaboration and teamwork bringing together experts from multiple fields and fostering relationships with healthcare providers, research institutions and biopharmaceutical partners.

PEOPLE

Meet the Team

Meet our leadership team and advisors. Our multidisciplinary team brings expertise across machine learning, pathology, medicine and biology.

Leadership Team

Thomas Colarusso

Chief Executive Officer & Cofounder

Alan Jerusalmi, PhD

Chief Innovation Officer & Cofounder

Troy Sarich, PhD

Chief Strategy & Commercial Officer; Board Member

Mike Bonham, MD, PhD

Chief Pathologist & Executive Medical Director

Sweta Bajaj, MS, Director of Computer Vision and Machine Learning at BioAI Health

Sweta Bajaj, MS

Director of Computer Vision and Machine Learning

Board of Advisors

Hon. Prof. Tom Chittenden, PhD, DPhil, DSPE

SAB Chairman; Chief Scientific Officer, Profound Therapeutics; Honorary Professor of AI in Biomedicine, Queen Mary University of London

Paolo Ascierto, MD

Director of the Department of Melanoma Cancer Immunotherapy, Institute of National Tumor IRCCS Foundation

J. Carl Barrett, PhD

Chief Scientific Officer, Precede Biosciences

Carlo Bifulco, MD

Chief Medical Officer of Providence Genomics, Medical Director, Translational Pathology, Earle A. Chiles Research Institute

Greg Slabaugh, PhD

Professor, and Director of the Digital Environment Research Institute (DERI), Queen Mary University of London

Drew Watson, PhD, MBA

Sr. VP Clinical Studies and Biostatistics, CellMax Life

Michael Rivers, MS, MBA

Former General Manager & VP Life Cycle Leader Digital Pathology, Roche Diagnostics

Jill Stefanelli, PhD, BioAI Health advisor

Jill Stefanelli, PhD

Chief Executive Officer, Modella AI (acquired by AstraZeneca)

Gina Wallar, PhD, BioAI Health advisor

Gina Wallar, PhD

Senior Vice President, Clinical Trials, R&D, Sonic Healthcare

Martin Baatz, PhD

Former General Manager, AstraZeneca Computational Pathology

Peter Blume-Jensen, MD, PhD

President and CEO, Acrivon Therapeutics